Using a backward logistic regression model, lower functional capacity between the default-mode network and ventral attention network accurately predicted response to cognitive rehabilitation among a cohort of patients with MS.
In addition to reductions of SOD1 protein, earlier start tofersen demonstrated positive effects in clinical function, respiratory function, muscle strength, and quality of life in patients with SOD1 ALS.
The associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center discussed the ways clinicians go about properly prescribing exercise regimens for patients with spinal muscular atrophy. [WATCH TIME: 3 minutes]
At year 5, significantly lower annualized change in EDSS score, lower incidence of confirmed disability worsening, and lower annualized change in FSS pyramidal function were identified in the early initiated treatment group.
Data from a cohort of more than 111,000 women showed that presence of endometriosis increased stroke risk by 34%.
Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.
The director of the John P. Hussman Institute for Human Genomics at the University of Miami detailed a new international initiative that expands on the genetic backgrounds of people of Hispanic and African ancestry. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
The median time to seizure relapse following antiseizure medication discontinuation was 8 months, although 16.7% of the cohort had relapse occur just 1 month after baseline.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.
Get caught up on some of the latest news in headache and migraine, with data updates and expert insights, all in one place from the NeurologyLive® team.
For amyloid positive cognitively unimpaired individuals, the best predicting compositive measure included gender, and changes in ADAS delayed recall, MMSE, SDMT, and Trailmaking Test B.
Neurology News Network for the week ending July 23, 2022. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 22, 2022.
For most of the individuals assessed, the rate of improvement was modulated by practice frequency, with significantly greater improvement over time in those who practice 3 to 5 days per week than those who completed 1 day of sessions per week.
The associate professor of rehabilitation and regenerative medicine at Columbia University Medical Center provided insight on the tools and gaps in care for assessing physical capacity in patients with spinal muscular atrophy. [WATCH TIME: 4 minutes]
In previous clinical studies, patients with AADC deficiency treated with the recombinant AAV2-based gene therapy achieved motor milestones, including head control and unassisted sitting.
As previous literature has suggested a link between NAFLD and cognitive dysfunction, new findings showed that the disease was associated with a 38% higher rate of dementia.
Treatment with CNM-Au8 was well-tolerated, with no new safety signals, and decreased the risk of death by 70% compared with placebo on unadjusted Kaplan-Meier analyses.
Findings showed between a 2.4- to 5-fold increased risk of autism spectrum disorder and intellectual disability in children with prenatal exposure to valproate, and similar findings for those exposed to topiramate.
The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared towards understanding genetic differences of underrepresented groups. [WATCH TIME: 6 minutes]
The Rapid Hyperdensity tool uses noncontrast CT scans to evaluate the hyperdense tissue volume during the identification and assessment of intracerebral hemorrhage.
Expected to be marketed as Lumryz by Avadel Pharmaceuticals, the extended-release oral suspension sodium oxybate’s final approval is pending the disposition of the REMS patent listed in the FDA’s Orange Book.
The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the state of treatment for status migrainosus and whether or not the new migraine medications can help improve care. [WATCH TIME: 2 minutes]
As scientific researchers continue to uncover new genetic links to amyotrophic lateral sclerosis, the rise of gene therapies to treat the neuromuscular disease will remain a development to watch in the coming years.
The vice president of clinical development at Biohaven provided insight on a new phase 3 study assessing a muscle-targeted agent as an adjunct therapy to currently approved spinal muscular atrophy medications.
Jill Farmer, DO, MPH, director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute, spoke at length about the recent ATMRD Congress, the state of care for movement disorders, and her hopes for the horizon of therapy and treatment.
Over a year treatment period, patients maintained their subscale scores assessing medication effects, energy and fatigue, and cognition, all of which might be expected to be sensitive to a new treatment.
The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about the need for clinicians to have more time with patients in clinical practice, particularly with those with chronic diseases. [WATCH TIME: 2 minutes]
Using rigorous cell-based assays, cerebrospinal fluid GFAP levels were significantly lower in double-seronegative NMOSD than AQP4-positive NMOSD but did not differ between those with MOGAD or other neurological diseases.
